Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

The goal of this study is to develop an algorithm using artificial intelligence (AI) to assist identification of potential ATTR-CM cases using routine transthoracic echocardiography. The main questions it aims to answer are: * is the algorithm able to diagnose ATTR-CM * is the algorithm able to diagnose different types of ATTR-CM (ATTRv, ATTRwt) This is a non interventional study. Participant' echocardiographies will be, after deidentification, used to train, valid and test the algorithm.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Cardiac transthyretin amyloidosis diagnosed on the classic criteria:

‣ Absence of monoclonal immunoglobulin AND

⁃ Presence of a bisphosphonate scintigraphy with enhancement in the cardiac area OR

• 2-Presence of a cardiac biopsy showing transthyretin (Congo red positive) cardiac amyloidosis (demonstrated either by immunostaining or by mass spectrometry) OR 3-Presence of a peripheral biopsy showing transthyretin amyloidosis (see above) associated with cardiac infiltration (parietal thickness \>12mm without other cause of cardiac hypertrophy)

• No opposition to research

• Indication for transthoracic echocardiography as part of cardiological follow-up

• Patient affiliated with social security

• Patient's agreement to participate in the research and signature of the consent form.

• Technical conditions of the examination and echogenicity allowing acquisition of good quality echocardiographic images, allowing post processing

Locations
Other Locations
France
Bichat
RECRUITING
Paris
Contact Information
Primary
Vincent Algalarrondo, MD, PhD
vincent.algalarrondo@aphp.fr
+33140257785
Backup
Gregory Ducrocq, MD, PhD
gregory.ducrocq@aphp.fr
+33140256600
Time Frame
Start Date: 2022-01-01
Estimated Completion Date: 2026-01-01
Participants
Target number of participants: 15000
Treatments
Transthyretin cardiac amyloidosis (ATTR-CM)
Patients with an ATTR-CM and undergoing a transthoracic echocardiography
Controls
Patients without cardiac amyloidosis undergoing transthoracic echocardiography as part of cardiological follow-up
Sponsors
Collaborators: Bichat Hospital, Bioquantis
Leads: Algalarrondo Vincent

This content was sourced from clinicaltrials.gov